Bibliography for Item 12 in BGP: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
Line 41: Line 41:


* Rohan, Dennis M., Alicia Seiger ''Note On The Biopharmaceutical Industry'', Stanford Graduate School of Business, 2003, https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1785
* Rohan, Dennis M., Alicia Seiger ''Note On The Biopharmaceutical Industry'', Stanford Graduate School of Business, 2003, https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1785
**You probably can get this through your University. If you can't ask Roxy the favor of downloading this papers and sending to you. She is a RA in Aarons group that also work in HBS. Her email is "Roxanna Myhrum" <
**You probably can get this through your University. If you can't ask Roxy the favor of downloading this papers and sending to you. She is a RA in Aarons group that also work in HBS. Her email is "Roxanna Myhrum" <rmyhrum@cyber.law.harvard.edu> and "Roxanna Myhrum" <rox.myhrum@gmail.com>.
rmyhrum@cyber.law.harvard.edu> and "Roxanna Myhrum" <rox.myhrum@gmail.com>.


==Navigation==
==Navigation==
[[Open Business models in BGP]]<br>
[[Open Business models in BGP]]<br>
[[Biotechnology_-_Genomic_and_Proteomics]]
[[Biotechnology_-_Genomic_and_Proteomics]]

Revision as of 23:01, 15 March 2009

Resources

  • Lakhani, Karim R. and Lars Bo Jeppesen, Peter A. Lohse and Jill A. Panetta, The Value of Openness in Scientific Problem Solving, Technology and Operations Management, No. 07-050, January 2007.
    • Complete Text (Acrobat PDF Version) Openness and free information sharing amongst scientists are supposed to be core norms of the scientific community. However, many studies have shown that these norms are not universally followed. Lack of openness and transparency means that scientific problem solving is constrained to a few scientists who work in secret and who typically fail to leverage the entire accumulation of scientific knowledge available. We present evidence of the efficacy of problem solving when disclosing problem information. The method’s application to 166 discrete scientific problems from the research laboratories of 26 firms is illustrated. Problems were disclosed to over 80,000 independent scientists from over 150 countries. We show that disclosure of problem information to a large group of outside solvers is an effective means of solving scientific problems. The approach solved one-third of a sample of problems that large and well-known R & D-intensive firms had been unsuccessful in solving internally. Problem-solving success was found to be associated with the ability to attract specialized solvers with range of diverse scientific interests. Furthermore, successful solvers solved problems at the boundary or outside of their fields of expertise, indicating a transfer of knowledge from one field to others. 58 pages

(I have this Pisano's book - Science Business...It is worth reading to find information about the field) Brendan: got it from the library. very helpful

  • Rohan, Dennis M., Alicia Seiger Note On The Biopharmaceutical Industry, Stanford Graduate School of Business, 2003, https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1785
    • You probably can get this through your University. If you can't ask Roxy the favor of downloading this papers and sending to you. She is a RA in Aarons group that also work in HBS. Her email is "Roxanna Myhrum" <rmyhrum@cyber.law.harvard.edu> and "Roxanna Myhrum" <rox.myhrum@gmail.com>.

Navigation

Open Business models in BGP
Biotechnology_-_Genomic_and_Proteomics